INTRODUCTION
The immune surveillance and killing activity of immunoactive cells on tumor cells play crucial roles in tumor immunity. However, oncologists and immunologists have long been faced with a tough task, i.e. how to successfully induce anti-tumor cytotoxic effects mediated by antigen specific T lymphocytes? [1] Research has revealed that one major reason for the low responsiveness of cytotoxic T lymphocytes (CTLs) to cancerous cells lies in the loss of interaction between costimulatory factors CD28 and CD152 and B-7 molecules on tumor cell surface which results from the low expression of the costimulatory factors of B-7 family on the surface of tumor cells [2, 3] . This precludes CTLs partially activated after recognition of antigens 978-1-4244-4692-6/09/$25.00 ©2009 IEEE 213 from being fully activated, making it impossible to generate cytokines with immunological attacking activity against tumor cells and membrane lysis signals (from the Fas-FasL system) as well.
In the present study, we constructed the recombinant adenovirus vector (AdV) containing the human FasL and B7-1 genes (termed FB-ll), which was used to transfect human gastric cancer cells. Transfection rates and the expression of the two genes were determined, and the capability of in vitro inducing tumor-specific CTLs from peripheral blood T lymphocytes (PBT) and tumorigenicity in mice of the FasL/B7-1 modified gastric cancer cells were observed. This provides experimental base for the combination of tumor immunology and gene therapy in the treatment of cancer.
MATERIALS AND METHODS

Animals, cells, materials
C57BL/6 (H-2b) inbred mice at the age of 6-8 weeks were bought from the Shanghai Laboratory Animal Research Center of Chinese Academy of Sciences. SV40 promoter (P SV40 ) driven human B7-1 eDNA was presented by Professor Darn Lu at the Institute of Molecular Genetics, Fudan University, Shanghai. Rat-anti-mouse monoclonal antibody (mAb) against B7-1 was purchased from Pharmingen Corporation, San Diego, CA, USA. Alkaline phosphatase-conjugated goat-anti-rat IgG was obtained from Organon Teknika Corporation, Durham, NC, USA. G418 was the product of Gibco. CMV promoter (P CMV ) containing human FasL eDNA and its labeled antibody were manufactured by Jinmei Company, Shanghai, China.
Human gastric cancer cell lines SGC-7901 were provided by the Institute of Cell Biology of Chinese Academy of Sciences, Shanghai. The cells were grown in RPMI-1640 supplemented with 10% fetal calf serum at 37°C in a 5% CO 2 atmosphere.
Human embryonic kidney cell line 293 containing El region of human adenovirus type 5 (Ad5) was bought from GeneTherapy Unit of Baxter Healthcare Company, USA and cultured in high glucose Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal calf serum at 37°C in a 5% CO 2 atmosphere. 
Construction ofrecombinant adenovirus
Tumorigenic test
A total of 7 C57BL/6 mice were randomly divided into two groups, test (n=4) and control (n=3) groups. The test group received an subcutaneous inoculation with 5x 10 6 SGC-790I/FB-Il cells in dorsal skin and the control group received an inoculation with the same number of SGC-790I cells at the same site. The growth of subcutaneous tumors was monitored by measuring long and short diameters with a slide gauge. The size of the tumors was expressed in long diameter x short diameter. Tumor sizes ofthe test and control groups were compared. Immunological protection test Four mice which were sensitized with SGC-790l/ FB-ll cells were inoculated with 2.5x 10 6 wild-type SGC-790I cells subcutaneously in the dorsal skin. Meanwhile, 4 normal mice were inoculated with the same number of SGC-790I cells at the same site as normal controls. Sizes of the subcutaneous tumors were monitored and compared between the two groups.
In vitro cytotoxic test
Mice were sensitized with 5x 10 6 SGC-7901 and SGC-790I/FB-ll cells peritoneously and sacrificed 7 days later. The abdominal cavity was then lavaged with 5 ml Hank's solution, which was subsequently aspirated and depleted of red blood cells. The remaining macrophages and tumor cells were removed by attachment to the wall so that abdominal infiltrating lymphocytes were obtained. In addition, erythrocyte-free single cell suspension of mouse splenocytes were prepared. Cytotoxic activity of activated CTLs was determined in vitro by MTI assay.
Statistical analysis
All statistical analysis in this study was performed with SPSS VlO.0 for Windows (SPSS Inc., Chicago, IL, U.S.A.) and P value of < 0.05 was considered significant.
RESULTS
B7-1 gene expression
Results from flow cytometry indicated that SGC-790I gastric cancer cells don't express B7-1 gene (Fig. I) . But there're 37.5% of the cells expressing B7-1 on cell surface I day after they were transfected with FB-ll at a MOl of 50, and 80% expressing high level B7-1 after 2 days. min at 55·C, and 1.5 min at n·c. PCR products were separated by electrophoresis on a 2% agarose gel and visualized by ethidium bromide (EB) staining, revealing a 231 bp band corresponding to human FasL gene fragment. Furthermore, the PCR products were analysed by restriction enzyme mapping. Inhibitive effects ofFB-ll on SGC-7901 cells growth SGC-790 I cancer cells were plated in 24-well plates at a density of I x 10 6 cells/well, and infected with FB-II or Ad-GFP at a MOl of 50 after 24 hr. Subsequent growth of the two cells was monitored daily. The cells were trypsinized, stained with trypan blue, and counted by a hemacytometer, and the growth curve was plotted.
Measurement of apoptosis in the FB-ll transfected gastric cancer cells by Hoechst33342 staining
Suspended FB-II transfected SGC-790 I gastric cancer cells were passed through filters and adjusted to a concentration of 5x 10 5 cells/ml. Then the cells were fixed in I% formaldehyde in I x phosphate buffered solution (PBS) for 30 min at 4·C . After two washes in I x PBS, 0.5 ug/ml Hoechst33342 was added, followed by incubation at 37"C for 2 hr. After being washed in I x PBS, the number of apoptotic cells were counted by fluorescence microscopy. In detail, a total of 200 cells were observed and only cells with typical characteristics of apoptosis counted as apoptotic according to principles proposed by 214 A: SGC-7901 B: SGC-790I/FB-I1.
as expected (Fig. 2) .
A B C Figure 2 RT-PCR analysis of FasL expression in SGC-7901 and SGC-790I/FB-ll A: SGC-790IlFB-ll; B: SGC-7901; C: DNA Marks Inhibitive and cytotoxic effects of FB-ll on gastric cancer cells As compared to non-infected cells, the growth of FB-II transfected SGC-790I gastric cancer cells was significantly inhibited (Fig. 3) with SGC-790I/FB-ll displaying more significant inhibition. CDS+ CTLs, which take on the responsibility of resisting virus and microorganism invasion and antineoplasm, recognize and kill MHC-I carrying target cells. CD4+ CTLs, which have the activity of immune regulation such as transplantational immunity, eliminate MHC-II carrying cells. However, when the cytotoxic activity of CDS+ CTLs is impaired especially on the occasion that MHC-I molecules are not or low expressed in tumor cells, CD4+ CTLs will act as major cytotoxic effectors. The cytotoxic activity of non-specific mitogen activated CD4+ T lymphocytes and mouse splenocytes within 24 hr of the activation results mainly from upregulation of FasL expression which binds to Fas receptor, initiating programmed cell death-apoptosis.
CTLs are major effector cells in immune system. T cell cytotoxicity is mediated by two independent cytolytic mechanisms [5-7 1 , namely release of perfurin acting on target cells and membrane binding or release of FasL acting on Fas-expressing cells. Degranulization of CTLs and perfurin-induced cytolysis are two separate steps of the specific cytotoxic process, which requires the recognition of the T cell receptor (TCR) and MHC molecules on the surface of target cells and involves perfurin, granzyme, Ca 2+ and ICE family etc. However, the Fas-FasL system mediates a non-specific, non-MHC restricted cytotoxicity. In the absence of Ca2+ or perfurin and granzyme, the cytotoxicity of in vivo and in vitro cultured CTLs is completely dependent on the Fas-FasL system. It is now believed that Fas-dependent cytotoxicity of CTLs comprises two steps: first, CTLs recognize Fas carrying cells and are activated to express FasL; Secondly, the CTL-expressed FasL binds to the target cell-carried Fas, leading to target cell apoptosis. Since the FasL-induced apoptosis does not rely on MHC and Ca 2+, the cytotoxic activity of FasL+-CTLs is not only broad-spectrum but also Fas+-cell targeted. Tumor cells always express Fas so FasL and CTLs are two important weapons against tumors. These are the rationale for the co-delivery ofFasL and B7-1 genes in the present study.
FasL is a 40-kDa type II trans-membrane protein which is a member of the TNF family. It used to be believed that only activated T cells express the FasL, but later studies demonstrated the expression of this cytokine on several other species of cells including neutrophils, neurons, thyrocytes, retinal stromal cells, salivary gland cells and mouse testicular podocytes [8] [9] [10] [11] .
Fas and FasL bind in a trimer style, leading to apoptosis in Fas-expressing cells. The interaction between Fas and FasL is currently believed to take place in the following fashions [12] : (1) Target cell apoptosis induced by T cells which is the most common situation, Le., FasL+-T cells (mostly CD8+) lead Fas-expressing target cells to apoptosis; (2) Induction of apoptosis between T cells, Le., activated T cells express both FasL and Fas so that apoptosis is induced at one or both sides of interacted T lymphocytes, which can result in diminution of immune responses; (3) Apoptosis induced between target cells, Le., like activated T cells, the target cell expresses both Fas and FasL, leading to apoptotic death at one or both sides of interacted target cells. Fas-FasL induced apoptosis between different types of cells is called trans apoptosis, and in contrast, apoptosis induced between cells of one type is called cis apoptosis. Based on the above-mentioned theory, we transduced FasL and B7-1 genes into human gastric carcinoma cells by adenoviral vector and hoped to achieve cis apoptosis between tumor cells and trans apoptosis in tumor cells induced by T cells whose activation was expanded through B7-1 gene delivery.
Antitumor immunity in human body is mainly T cell-mediated cellular immune responses. T cells require three signals to become activated. The first signal is through the T cell receptor (TCR) to which specific Ag-MHC complex binds. The binding activates TCR-CD3 complex and then CD3 molecule transducts the binding signal into CTLs. The second signal is co-stimulating signal [12] [13] [14] [15] . CTLs are activated by the intercellular contact mediated by CTL surface adhesive molecules. One example is the interaction between the CTL surface molecule CD28 and the molecule B7-1 on the surface of antigen-presenting cells (APC) and tumor cells, which is thought to have a important role in CTL activation. The third signal is the stimulation of cytokines like IL-2 etc. One recent great progress in the field of antitumor therapy is the expansion of tumor-specific CTLs by non-specific methods in vitro [22] . In preclinical studies, the vitality and specificity of in vitro CTL cultures can be maintained by intermittent stimulation by tumor cells or tumor antigens, thus to acquire large quantities of tumor-specific CTLs for in vivo anticancer therapy. However, this method cannot be used to expand human tumor-specific CTLs. One reason is for the risk of using human cancerous cells as 216 stimuli, and another is that though the presence of CTL-recognized human tumor antigens has been confrrmed, it's hard to purify such antigens to expand CTLs. Therefore, the in vitro expansion of tumor-specific CTLs by way of transfection of genes of non-specific mAbs (anti-CD3 and anti-CD28), cytokines (IL-2) and B7-1 has great prospects in current adoptive immunotherapy and gene therapy for the treatment of cancer. But the feasibility of this method in clinical practice lies on the availability of large amounts of expanded tumor-specific CTLs with high antitumor cytotoxicity of clinical standard. In this study, the transfection of B7-1 gene promoted expansion and activation of CTLs and the transfection of FasL gene gave rise to cis apoptosis in tumor cells. But an important innovation of this study is that the co-delivery of the two genes resulted in arrest of tumor cell growth, which has not been reported at home and abroad.
Research has showed that during the effect phase of co-stimulatory molecules, interactions between CD28 and CD86 and between CD 152 and CD80 generate cytolytic signals leading to tumor cell death. Membrane lysis caused by the Fas-FasL interaction is one of the effects. Tumor cells do express Fas and the Fas is capable of transducting cell apoptotic signals. These are the two prerequisites to the application of anti-Fas antibody and FasL transfection in the treatment of cancer. As yet, the FasL gene has not been reported to be used in the treatment of gastric cancer. To study the role of the Fas-FasL system in gastric cancer cell apoptosis, Liu HF et al [16] measured the expression of Fas and FasL in gastric cancer cells and found that some cells had low expression of Fas but with high expression of FasL. This is the same as previously reported that the expression of Fas in some cancer cell lines was downregulated or lost [17] . Many human tumor cell lines have no or low expression of Fas, and this probably results in the incapability of T cells inducing apoptosis of tumor cells, which is a probable reason for the escape of tumor cells from immune surveillance and tumor formation and progression. However, other studies [18] [19] [20] have demonstrated that the expression of FasL on tumor cells and islet cells didn't have immune protective action, but on the contrast, the FasL-expressing cells were destroyed because of the infiltration of large amounts of granulocytes. Whereas tumors cells have low or no expression of Fas and high expression of FasL on some occasions, it's necessary to in-depthly explore the mechanisms of regulation of Fas/FasL on the surface of tumor cells.
Some cytokines including IFN-y, TNF-a and IL-2 upregulate the Fas expression, and the transfection of FasL in Fas --tumor cells can induce inflammatory reactions [18] [19] [20] . In addition, B7-1 overexpression induced interaction between co-stimulatory molecules increases the expression of the above-mentioned cytokines during the effect phase. The results of this study revealed that: (1) FB-II transfected human gastric cancer cells had lower tumorigenicity and newly-formed tumors regressed in short time. But the control group had persistently growing tumors. This suggests that FB-II containing gastric cancer cells acquired cis apoptosis as well as the ability to induce strong immune responses. The mechanism for this reaction is that with the co-stimulatory effects ofB7-I, CTL clones specific for the major epitopes on the gastric cancer cells were amplified to a greater degree, and meanwhile, B7-I co-stimulatory signaling uncovered the sub-dominant epitopes on the surface of gastric cancer cells. This caused the sub-dominant epitope-specific CTL precursors to become activated and proliferate, and induced immune reactions [21] . However, these sub-dominant epitopes are not able to arouse immune reactions in usual cases. (2) Primary tumors in C57BL/6 mice inoculated with FB-II transfected human gastric cancer cells could regress, and reimplantation of wild-type gastric cancer cell lines in mice sensitized with FB-II transfected gastric cancer cells couldn't result in new tumor formation. The reason for this is that tumor-specific CTL clones were activated by the sub-dominant epitopes on the gastric cancer cell surface together with the co-stimulatory molecule B7-1. Hereby immune responses occurred immediately upon the inoculation with wild-type cancer cells with the same antigens. (3) The activation of T cells requires the co-stimulatory signal of B7-I. But for the post-activation effect phase, most researchers believe that the participation of B7-I is not essential. However, conflicting results were produced in some other studies [22, 23] . In the study presented here, results from protective immune test showed that FB-II transfected gastric carcinoma cells sensitized mice rejected new implant of wild-type cancer cells, and activated CTLs had efficient cytotoxic activity on FB-II+-cancer cells, suggesting that the cytotoxicity of activated CTLs can be induced without B7-I co-stimulatory signaling. Results from in vitro cytotoxic assay revealed that FB-II + gastric cancer cells-activated CTLs had greater killing activity on FB-II+ gastric cancer cells than on wild-type cell lines, suggesting that both FasL and B7-I molecules play crucial roles in the effect phase. The probable mechanisms are that overexpression of FasL recruits a great many inflammatory cells, leading to local immune responses; released inflammatory cytokines can in turn enhance CTL activation and proliferation; the binding of B7-1 to CD28 facilitates adhesiveness between lymphocytes and tumor cells; the binding of B7-I to CD28 promotes the binding of polypeptides-MHC complex to TCR, and in other words, B7-I can lower the threshold value of T cell responses. Therefore, we propose that the molecule B7-I is not essential in T cell effect phase, but it can boost the cytotoxic activity of T cells.
In conclusion, tumor cells express Fas and also express FasL sometimes. Overexpression of FasL/B7-I genes in tumor cells don't cause "immune counteraction" against CTLs, but can elevate the Fas expression in tumor cells themselves through inflammatory reactions, which 217 facilitates the performance of CTL cytotoxicity on tumor cells. Overexpression of FasL can still increase the immunogenicity of the gastric cancer cell lines in the presence of overexpressed B7-I gene, which promotes the development of antitumor immunity in mice. Overexpression of both tumor immunity-associated gene B7-I and apoptosis-inducing gene FasL in one gastric cancer cell line can generate synergistic anti-tumor activity.
